Actinium Pharma – Pivotal Results From Key New Drug In The Fight Against Cancer

Sandesh Seth, CEO & Chairman of the Board of Actinium Pharmaceuticals (NASDAQ: ATNM), was recently a guest on Benzinga’s All-Access.

Actinium is a clinical-stage biopharmaceutical company developing targeted radiotherapies to deliver cancer-killing radiation with cellular level precision to treat patients with high unmet needs.  

Actinium's clinical pipeline is led by radiotherapies that are being applied to targeted conditioning, which is intended to selectively deplete a patient's disease or cancer cells and certain immune cells prior to a bone marrow transplant (BMT), gene therapy or adoptive cell therapy. This allows for higher success rates.

Mr. Seth discussed his company’s promising results and what it means for the future of its lead drug candidate. 

Watch the full interview here:

Featured photo by National Cancer Institute on Unsplash.
This post contains sponsored content. This content is for informational purposes only and not intended to be investing advice.